ALXO•benzinga•
ALX Oncology Unveils Clinical Development Plans For ALX2004, A ADC Targeting EGFR-Expressing Tumors, With Phase 1 Trials Set For Mid-2025 Following FDA IND Clearance And Initial Data Expected In 1H 2026, While Advancing CD47-Blocker Evorpacept In Breast A
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 20, 2025 by benzinga